Israel - hebreu - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

Israel - hebreu - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

Israel - hebreu - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

Israel - hebreu - Ministry of Health

glaxo smith kline (israel) ltd - clobetasol 17- propionate - משחה - clobetasol 17- propionate 0.05 %w/w - clobetasol - clobetasol - resistant dermatoses responsive to potent corticosteroid therapy.

Israel - hebreu - Ministry of Health

glaxo smith kline (israel) ltd - clobetasol propionate - תמיסה - חיצוני - clobetasol propionate 0.05 %w/w - clobetasol - clobetasol - for the topical treatment of inflammatory conditions of the scalp responsive only to corticosteroids.

Israel - hebreu - Ministry of Health

glaxo smith kline (israel) ltd - clobetasol 17- propionate - קרם - clobetasol 17- propionate 0.05 %w/w - clobetasol - clobetasol - resistant dermatoses responsive to potent corticosteroid therapy.

Israel - hebreu - Ministry of Health

teva israel ltd - desmopressin acetate - טבליה - desmopressin acetate 0.1 mg - desmopressin - desmopressin - desmopressin teva tablets are indicated for central diabetes insipidus, nocturnal enuresis ( in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. the treatment must be started befor the age of 65.

Israel - hebreu - Ministry of Health

teva israel ltd - desmopressin acetate - טבליה - desmopressin acetate 0.2 mg - desmopressin - desmopressin - desmopressin teva tablets are indicated for central diabetes insipidus, nocturnal enuresis ( in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. the treatment must be started befor the age of 65.

Israel - hebreu - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as acetate - powder for suspension for injection - triptorelin as acetate 3.75 mg/vial - triptorelin - triptorelin - lowering sexual hormones, prostate cancer, endomedtriosis, uterus myomatosus, fertility treatment ivf. central precocious puberty.

Israel - hebreu - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as embonate - suspension for injection - triptorelin as embonate 3.75 mg ml - triptorelin - triptorelin - lowering of sexual hormones and treatment of advanced prostate cancer. central precocious puberty.